Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic ... that demand for weight-loss drugs isn’t as high ...

A new study shows that Ozempic may help ease arthritis knee pain in people with obesity. Here's what to know about the study and whether semaglutide can truly help reduce knee pain, according to ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good morning. My name is Alan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx ...

clinical data has demonstrated weight loss effects comparable to or even better than multi-target GLP-1 once-weekly formulations, providing new insights for the future development of GLP-1 drugs. The ...

Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Like Ozempic and Wegovy, liraglutide is an injected GLP-1 receptor agonist that can suppress appetite and regulate hunger ...

Nearly 80% of adults find the cost of prescription drugs to be unreasonable, and the high cost of GLP-1 receptor agonists ...